David Hallal, Scholar Rock CEO, joins 'Fast Money' to talk its recent drug study results that found its drug taken in ...

View the latest Scholar Rock Holding Corp. (SRRK) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Scholar Rock's Apitegromab excels in Phase 2 trials, aiding muscle preservation with Tirzepatide. Click here to read why I ...

FLAT ROCK, MI — Flat Rock Community Schools announced the top 10 graduates in the Flat Rock High School Class of 2025. The ...

We recently published a list of These 10 Stocks Boast Double-Digit Gains Amid Boring Market. Scholar Rock Holding Corporation ...

Shares of Scholar Rock Holding ( SRRK 13.36%) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 ...

Scholar Rock (NASDAQ: SRRK) has reported positive results from the phase 2 Embraze trial, demonstrating statistically ...

An unknown assailant in Washington D.C. attacked a gay man with a rock, causing him to bleed profusely. The victim suspects his attacker may be a young local teen who has yelled homophobic slurs ...

Learn about the executive team and board of directors at Scholar Rock Holding Corp (SRRK:XNAS) and review their bios and compensation over the latest fiscal years.

The Dome of the Rock, an architectural masterpiece and Islam’s third most sacred site, is revealing its secrets to scholars who were granted groundbreaking access.

Scholar Rock Holding Corp. stock grades by Barron's. View SRRK fundamental and sentiment analysis powered by MarketGrader.

Popular rock frontman battling stage 4 cancer. Here’s the latest . Published: Jun. 07, 2025, 6:15 a.m. 3 Doors Down frontman Brad Arnold is battling cancer. Scott Legato| Getty Images. By .